ArticleFrontiers in endocrinology2025
Identification of lactylation-related biomarkers in osteoporosis from transcriptome and single-cell data.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The emerging role of lactate in skeletal homeostasis and disorders: Integrated mechanisms and translational opportunities.Journal of orthopaedic translation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence indicates that lactase-mediated histone lactylation can activate osteogenic gene expression and promote bone formation. However, the role of lactylation-related genes (LRGs) in osteoporosis (OP) remains unclear. This study aims to clarify the key roles of LRGs and the molecular mechanisms of related biomarkers in OP. Methods: Three datasets (GSE7158, GSE56815, and GSE147287) and 327 LRGs were analyzed in this study. First, the biomarkers associated with OP were identified through differential gene expression analysis, machine learning algorithms, expression validation, and receiver operating characteristic (ROC) curve analysis. Subsequently, nomograms, functional enrichment analyses, immune infiltration analyses, regulatory network construction, drug prediction, and molecular docking were performed to characterize the functional and clinical significance of the biomarkers. Single-cell analysis was used to screen key cell types. Finally, reverse transcription quantitative polymerase chain reaction (RT-qPCR) was conducted to validate biomarker expression. Results: CSRP2 and FUBP1 can serve as biomarkers for the early prediction of osteoporosis risk in individuals with low peak bone mass or bone mineral density. The nomogram showed that these two biomarkers could accurately predict OP risk. Functional analysis revealed that Conclusions: CSRP2 and FUBP1 can serve as biomarkers for the early prediction of osteoporosis risk in individuals with low BMD/PBM. The findings of this study offer critical clinical guidance for OP prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.